Objective: Cognitive deficits including impaired working memory are a hallmark feature of schizophrenia. Dopamine D1 receptor modulated changes in prefrontal cortex function play a potentially important role in the pathology underlying such deficits. However, pharmacological interventions that selectively engage the D1 receptor are severely restricted for research in humans. The present study is a proof-of-principle for enhancing cognitive performance and associated brain activation via indirect D1 stimulation, operationalised by combining the nonselective dopamine agonist L-dopa with the D2-antagonist haloperidol.
enhancing agents for schizophrenia represent a core unmet need: In addition to direct treatment of cognitive deficits, these agents may promote functional independence via improved insights into disease and therapy (Green, Kern, Braff, & Mintz, 2000) . Here, we aim to provide proof-of-principle evidence for a potential cognitionenhancing treatment, which could inform a novel treatment strategy for individuals with schizophrenia (Saha, Chant, & McGrath, 2007) . Dopamine D2 receptor antagonists are the most widely used class of pharmacological agents in schizophrenia. It is thought that D2 receptor blockade, primarily in striatum, is the main mechanism of action by which antipsychotics decrease positive symptoms. Importantly, however, D2 receptor blockade does not appear to explain the modest improvement in cognitive impairments seen in some patients (Goldberg et al., 2007) and treatment with second-generation antipsychotics does not improve working memory and attentional functions (Nielsen et al., 2015) , underlining the need for alternative approaches.
Preclinical research has established that dopamine D1 receptors essentially modulate prefrontal cortex (PFC)-mediated working memory (Sawaguchi & Goldman-Rakic, 1991) . For example, D1 agonism improves working memory in aged monkeys , whereas D1 antagonism negatively impacts spatial working memory abilities. At the neural level, D1 receptor activity increases signal-to-noise ratio (SNR) in neural networks, including PFC, most likely by decreasing spontaneous firing of neurons (Seamans, Gorelova, Durstewitz, & Yang, 2001 ). An optimal level of PFC dopamine activity has been described by many studies in experimental animals and humans, with insufficient and excessive D1 receptor activation leading to reduced SNR (Akaike, Ohno, Sasa, & Takaori, 1987) , and an inverted-U shaped relationship between dopamine activity and cognitive performance (Cools & D'Esposito, 2011) .
Cognitive deficits in schizophrenia may be the consequence of altered dopamine D1, rather than D2, function in PFC (Abi-Dargham et al., 2002) . This notion is supported by the observation that D1 receptor density in PFC correlates with cognitive performance in schizophrenia (Abi-Dargham, 2003) and schizotypal personality disorder (Thompson et al., 2014) . Moreover, in animal models of schizophrenia, D1 receptor agonism can reverse cognitive impairments (McLean, Idris, Woolley, & Neill, 2009) . In light of this evidence, D1 receptors have long been considered potential treatment targets (Goldman-Rakic, Castner, Svensson, Siever, & Williams, 2004) . Dopamine D1 receptors can be stimulated directly or indirectly, although currently available compounds have significant drawbacks (Arnsten, Girgis, Gray, & Mailman, 2016) . For example, amphetamine nonselectively enhances catecholaminergic and serotonergic activity, in addition to its abuse potential. The D1 receptor agonist SFK-38393 is potentially useful, as it reverses phencyclidine-induced cognitive deficits in experimental animals, but it has not been used in humans (McLean et al., 2009) . DAR-0100A is the only selective D1 receptor agonist available for use in humans. There are preliminary findings suggesting improved spatial working memory in schizotypal personality disorder (Rosell et al., 2015) and enhanced perfusion of prefrontal and nonprefrontal brain areas in schizophrenia patients . However, DAR-0100A did not improve executive functions or cognition-related brain function in schizophrenia , it has exclusively been used at doses that do not produce measurable D1 receptor occupancy (Slifstein et al., 2011) and produces a range of side effects . In addition, the agent's short half-life (Blanchet et al., 1998) complicates successful treatment.
An alternative and accessible approach is to increase dopamine turnover nonselectively and simultaneously block D2 receptors, hypothetically producing dopamine D1 receptor agonism. Dopamine turnover can be increased nonselectively by administration of its precursor L-dopa, which increases dopamine synthesis in the central nervous system and periphery (Rosen, Flemenbaum, & Slater, 1986) .
Peripheral increases in dopamine can be blocked by carbidopa, further increasing central dopamine availability (Rosen et al., 1986) .
Haloperidol has a mixed profile but acts principally as a dopamine D2-antagonist.
In the present proof-of-principle study, we hypothesised that simultaneous administration of L-dopa/carbidopa and haloperidol would decrease PFC brain activity and increase functional connectivity (Meyer-Lindenberg et al., 2001 ) during a working memory paradigm, possibly as a consequence of increased D1 activation. Here, drug-induced decreases in brain activity in combination with functional connectivity increases indicate more efficient network activity, the result of increased SNR . As drug-induced performance increases may be difficult to establish in healthy volunteers, who already function at a near-optimal level, we relied on the sensitive nature of BOLD fMRI during N-back task performance. The N-back is a well-established paradigm for probing working memory function has been used extensively in schizophrenia (e.g., Bertolino et al., 2003) and is sensitive to dopaminergic drug effects .
| METHODS

| Participants
We recruited 14 healthy right-handed male volunteers aged between 19 and 38 years (mean ± SD = 25.0 ± 5.1 years) by circular email sent to students and staff from King's College London who were financially compensated for their time. Using BOLD for the dorsolateral PFC (DLPFC) from in-house N-back data set, we estimated that with 14 participants we have a power of~0.55 to detect a 50% reduction in BOLD signal amplitude in the drug condition at p < 0.05. Inferences were planned for cluster correction statistics for which a priori power analyses is difficult. Participants' physical and mental status were assessed by a screening involving a urine analysis and test for the presence of drugs of abuse (amphetamines, methamphetamines, THC, methadone, opiates, phencyclidine, barbiturates, benzodiazepine, and tricyclic antidepressants), a 12-lead electrocardiogram, measurements of heart rate and blood pressure, breath alcohol concentration and blood chemistry and haematology.
Volunteers were excluded if they showed any evidence or history of clinically significant renal, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease/disorder, including epilepsy or seizures and more than one febrile convulsion. In addition, volunteers were excluded from the study if they used any prescribed or nonprescribed drugs except paracetamol and acetaminophen, drank more than 28 standard alcohol units per week, smoked more than five cigarettes per day, were treated with a new chemical entity within the past 3 months, had a known sensitivity to any of the study medications, a Body Mass Index outside the limits of 18-30 kg·m −2 , nonremovable metallic items in/on their body or signs of claustrophobia.
All participants gave written informed consent before they entered the study that was approved by the King's College Research Ethics Committee (RECnr.: 10/H0807/13) and was conducted in accordance with the World Medical Association Declaration of Helsinki and its amendments (World-Medical-Association, 1964 , 1996 .
| Experimental design and treatment
The study was carried out according to a two-way double blind, placebo-controlled design. Study medications were combined oral doses of haloperidol 2 mg and L-dopa 100 mg/carbidopa 25 mg or placebo (ascorbic acid) administered according to a double dummy procedure. Administration order was randomised and counterbalanced across participants. Haloperidol 2 mg was chosen because it has been shown to block 60-75% of D2 receptors and doses up to 3 mg are generally well tolerated according to the literature (Legangneux et al., 2000) and our own experience (Handley et al., 2013; Hawkins et al., 2018) . L-dopa 100 mg/carbidopa 25 mg was chosen because it is also well tolerated and produces minimal side effects in healthy volunteers (Floel et al., 2008; Symmonds, Wright, Fagan, & Dolan, 2013) . In addition, the dose of levodopa has been used in numerous previous studies in healthy volunteers, a dose that usually produces cognitive effects (Breitenstein et al., 2006; Knecht et al., 2004; Symmonds et al., 2013; Wittmann & D'Esposito, 2015) . At these doses, we expected side effects to be well tolerated, adding to protecting the blind. However, nausea occasionally occurs, which we aimed to prevent by administration of peripherally acting dopamine antagonist domperidone that was administered prior to the start of the experiment on both study days (drug and placebo).
| Procedure
The volunteers visited the Centre for Neuroimaging Sciences three times. The first visit was a screening/training visit during which volunteers gave their written informed consent, were medically screened, and performed the tasks in a mock scanner to familiarise them with the MRI environment and task procedures. The second and third visits were scanning visits. After confirming suitability (including a physical assessment conducted by a physician), subjective mood was assessed using 16 visual analogue scales (Bond & Lader, 1974) . Volunteers received haloperidol 2 mg and domperidone or placebo at time T0.
After waiting for 60 min, they received L-dopa 100 mg/carbidopa 25 mg or placebo (T60), ensuring that plasma peak levels of both drugs occurred at similar times (T max Haloperidol = 1.7-6.1 hr [Kudo & Ishizaki, 1999] , T max L-dopa = 15-60 min [Contin & Martinelli, 2010] ); 120 min after the administration of the first dose (T120) a second assessment of subjective mood was performed using the visual analogue scales. Volunteers received a small standardised lunch and entered the scanner 150 min after the first dose (T150). Visual stimuli were back-projected on a screen, which the volunteer could see using periscopic mirrors. After scanning, volunteers' subjective mood was assessed again. Finally, a physical examination was performed as part of a discharge assessment by the physician.
| Materials and tests
| N-back task
The N-back task is a well-established working memory task that reliably activates the DLPFC (Owen, McMillan, Laird, & Bullmore, 2005) and has been used in many studies to assess drug-induced changes in working memory performance The current version of the task consisted of four conditions: 1-back, 2-back, 3-back, and a 0-back control condition. Each task condition occurred three times as blocks of 14 letters sequentially presented on a screen for 2 s per letter.
Before each 28-s block of trials, the upcoming condition was briefly presented for 2 s. Volunteers responded to cues with a button press on a response box using their right index (target) and left index (nontarget) finger. A target stimulus was defined as a letter that matched the previous one in the 1-back condition (e.g., "A" followed by "A"), a letter presented two letters earlier in the 2-back condition (e.g., "A," "B," and "A"), a letter presented three letters earlier in the 3-back condition (e.g., "A," "B," "C," and "A") or was an X in the 0-back condition (e.g., "A," "B," and "X"). The total length of the task was 6 min and 20 s.
Reaction time and responses were recorded, and average reaction time and number of correct responses were dependent variables.
| Subjective mood ratings
Subjective evaluations of alertness, contentedness, and calmness were assessed using a series of 16 visual analogue scales (100 mm), which provided factor analytically defined summary scores for "alertness," "contentedness," and "calmness" (Bond & Lader, 1974) . Participants were asked to indicate their current mood state by marking a horizontal line in between two extremes of a given mood dimension, for example, alert-drowsy.
| Image acquisition
All MRI data were collected at the Centre for Neuroimaging Sciences, King's College London using a General Electric 3 Tesla Signa HDx scanner (General Electric, Milwaukee) with an eight channel head coil. 
| Image preprocessing
Imaging data were processed in SPM8 (http://www.fil.ion.ucl.ac.uk/ spm/) using Matlab (V7.0.1.; https://mathworks.com) on a UNIX platform. Slices were corrected for acquisition time using the middle slice as reference. The data were corrected for translational and rotational movement in three dimensions, first by registering all images to the first in the series and then to the mean image. In all runs, volunteer head movement did not exceed the limit of one voxel on no more than three occasions within one run, either translational or rotational (i.e., rotational limit equating to one voxel at the brain surface). The functional data were coregistered with the high resolution T1-weighted image data using the mean image to determine the parameters. The T1-weighted images were normalised to standard MNI space using unified segmentation with the parameters applied to the functional time series which were then smoothed using a Gaussian kernel of 8 mm of full width at half maximum. All scans were visually inspected for quality of preprocessing.
| Data and statistical analysis 2.7.1 | Behavioural data
Two participants did not perform above chance level on 2-back and 3-back trials, and their data were excluded from analysis. For the remaining 12 participants, a 2 × 4 general linear model for repeated measures analyses were performed for reaction time and correct responses, with treatment (two levels: haloperidol/L-dopa and placebo) and level of difficulty (four levels: 0-, 1-, 2-, and 3-back) as within subject factors.
We tested for a main effect of treatment and level of difficulty and their interaction at α = 0.05 significance level, corrected using Greenhouse-Geisser method when the sphericity assumption was violated. A significant main effect of level of difficulty was further specified using contrasts between 0-back condition and 1-, 2-, and 3-back condition. A significant interaction between level of difficulty and treatment was further specified using drug-placebo contrasts within each difficulty level.
Visual analogue scales data from all 14 participants were analysed separately for three factors (alertness, contentedness, and calmness) using general linear model for repeated measures with treatment (two levels: haloperidol/L-dopa and placebo), and time point (three levels: T0, T120, and T210) as within-subjects factors. Significance level was set at α = 0.05 and was corrected using Greenhouse-Geisser when the sphericity assumption was violated. All behavioural data were analysed using SPSS 18 (SPSS inc., 2009).
| Imaging data
For 12 participants performing above chance level, functional images were first analysed at the single-subject level in the framework of the general linear model. The design matrix comprised 11 regressors; 0-, 1-, 2-, and 3-back trial blocks, visually presented instructions, and three translational and three rotational movement parameters, for which Beta weights were estimated. Next, contrasts were defined between 0-back and 1-, 2-, and 3-back, representing activation during 0-back subtracted from activation during the other N-back difficulty levels. For the 2nd level analysis, all first level contrasts were resliced to match the FMRIB Software Library's (FSL; [Jenkinson, Beckmann, Behrens, Woolrich, & Smith, 2012] ) MNI152 2 mm template. Next, all contrasts images were concatenated into a single four-dimensional file.
Using FSL's randomise (Winkler, Ridgway, Webster, Smith, & Nichols, 2014 ) F-contrasts for treatment (two levels: haloperidol/L-dopa and placebo) and level of difficulty (three levels: 1-, 2-, and 3-back > 0-back contrasts), and their interaction were calculated in a model with treatment and level of difficulty as fixed factors and subject as random factor. Significant (TFCE, p < 0.05 FWE corrected) main effects or interaction were further analysed using t-contrasts.
In addition, generalised psychophysiological interaction (gPPI; Figure 1 and Table 1 for descriptive and significance statistics.
| Subjective mood ratings
Time point showed a significant effect on measures of alertness and contentedness. Alertness significantly decreased over time points and contentedness was lower at T120 compared with T0 and with T210. Drug treatment did not affect subjective ratings of alertness or contentedness. The treatment by time point interaction showed a trend, driven by haloperidol/L-dopa increasing calmness over time compared with placebo. Contrasts between haloperidol/L-dopa and placebo were significant or close to significance for differences between calmness measured at T210 and T0, and T210 and T120.
| Imaging data
| N-back: Level of difficulty effects
F-contrast for the main effect of Level of difficulty indicating any activation differences with 0-back resulted in a large number of significant clusters of activation (see Figure 2 ). In addition, t-contrasts assessing where brain activity increased with task difficulty revealed a number of significant areas in the 2-back > 1-back contrast, which closely resembled the activation pattern of the general F-contrast. In addition, the 3-back > 2-back t-contrast did not reveal any significant activity differences.
| N-back: Treatment effect
An F-contrast for treatment effects indicated significant activation differences between drug and placebo sessions. T-contrasts revealed that combined haloperidol/L-dopa administration significantly decreased brain activation in a wide range of regions compared with placebo (see Figure 3 and Table 2 ). Although no significant treatment by level of difficulty interaction was observed, planned t-contrasts did reveal a significant treatment effect during the 2-back condition. During the 2-back condition, combined haloperidol/L-dopa administration reduced activity in a large number of clusters that mostly overlapped with the clusters from the overall F-contrast for treatment. A noticeable exception was reduced activation in bilateral caudate, right amygdala, and right thalamus (see Figure 3 and Table 3 ).
| N-back connectivity
Planned exploratory t tests showed that combined haloperidol/L-dopa treatment increased task-dependent connectivity between DLPFC and several clusters for all N-back contrasts (1-, 2-, and 3-back vs. 0-back). The first cluster included right superior frontal gyrus (peak voxel at BA8), bilateral paracingulate gyrus (peak voxel at BA32), and right middle frontal gyrus (peak voxel at BA45). The second cluster included two peaks in the right premotor cortex (peak voxels at BA6). Finally, one cluster was detected in the left premotor cortex (peak voxel at BA6). Please see Figure 4 and Table 4 for details. None of the correlations between cluster peak voxel beta weights and the drug-body weight ratio were significant.
| DISCUSSION
Here, we provide preliminary data for the effects of combined haloperidol/L-dopa administration on working memory-related brain activation. It was hypothesised that the combined haloperidol/L-dopa administration would induce changes in brain activity associated with N-back task performance, potentially by increasing SNR. In line with this hypothesis, smaller drug-induced differences in activity for the 2-back versus 0-back contrast were observed in a large number of brain areas, most notably in the occipital/temporal cortex. Further, we observed drug-induced accentuated connectivity between DLPFC and right frontal brain areas (superior and middle frontal gyrus and paracingulate gyrus) as well as sensorimotor areas (bilateral premotor cortices).
FIGURE 1
Performance on different levels of N-back task difficulty after receiving placebo or a combination of L-dopa and haloperidol according to a within-subjects design (n = 12). No significant drug effects were observed, although drug treatment was followed by more accurate responses during 0-back and 1-back at a trend level (p < 0.1). HAL/DOP: haloperidol/L-dopa treatment; PLC: placebo FIGURE 2 Main effects of Level of difficulty (within subject variable, n = 12) on brain activation and contrasts between 1-back and 2-back and between 2-back and 3-back. Results indicate that the 2-back condition evoked network activation most robustly in premotor cortex (BA6), supplementary motor area (BA6), anterior cingulate (BA32), superior parietal lobule (BA7), inferior parietal lobule (BA40), Broca's area (BA44, 45), middle frontal gyrus (BA46), insula (BA47, 48), and frontal pole (BA10) dependent working memory performance (Rieckmann, Karlsson, Fischer, & Backman, 2012) , many of which were also observed in the present study (e.g., paracingulate and premotor cortex). Moreover, L-dopa enhanced memory load-dependent working memory performance that coincided with increased frontal low theta power (Eckart, Fuentemilla, Bauch, & Bunzeck, 2014) . In contrast, D2 blockade has been shown to decrease cortico-striatal connectivity in humans (Cole et al., 2013) and rats (Gass et al., 2013) at rest and decreases frontal cortical activity during tasks of response inhibition (Luijten et al., 2013 ) and working memory (Goozee et al., 2016) . However, drug-induced changes outside of the typical task network have been observed previously. Furey, Pietrini, Alexander, Schapiro, and Horwitz (2000) showed that cholinergic enhancement can increase extrastriate cortex activation during encoding, which was accompanied by better working memory performance and reduced requirements for prefrontal activity. Therefore, even though the extrastriate cortex is not typically involved in specific working memory processes, drug-induced modulation of its activation can coincide with changes in performance. receptors modulate working memory-related occipital cortex activation, and those effects are likely to be the result of altered activation of regions connected to the occipital cortex. However, the present study was not designed to provide direct evidence for the effects of haloperidol. Therefore, this conclusion should be considered with caution.
As no significant effects on performance were observed, the behavioural consequences of combined haloperidol and L-dopa administration remain unclear. Despite the small sample size, the nonsignificance of the drug-induced effects is in line with previous results suggesting that haloperidol 2 mg only has minor effects on cognitive performance, whereas higher doses from 3 mg do induce impairments (Legangneux et al., 2000) . Alternatively, higher L-dopa doses may have resulted in enhanced N-back performance, perhaps represented by increasing response speed, without decreasing accuracy (Eckart et al., 2014) .
A clear limitation of the present study is that it was designed as a proof-of-principle study to explore the potential effects D1 stimulation on working memory-related brain activation, operationalised by combined haloperidol/L-dopa administration. Therefore the study did not include all treatment conditions for a full factorial design and, thus, the contribution of L-dopa and haloperidol alone, as well as the interaction between treatments, could not be determined.
Nonetheless, within the context and current aim of understanding combined treatment effects, we were able to confirm dopamine enhancing effects as measured with fMRI as a highly sensitive measure to such changes.
The binding profile of haloperidol to presynaptic and postsynaptic receptors potentially complicates the interpretation of the results and, thus, needs to be considered. Indeed, this issue is relevant to all studies that administer dopaminergic stimulants, D2 agonists or D2 antagonists. Haloperidol can bind to both presynaptic and postsynaptic D2 receptors. The D2 presynaptic receptors are autoreceptors and binding to the presynaptic receptor causes an increase in extracellular dopamine levels (Lidsky & Banerjee, 1993) . Nonetheless, its postsynaptic D2 receptor blocking potential causes the desired reduction in D2 receptor mediated dopamine action, in line with our interpretation. For our particular study, the argument can be considered that the presynaptic effects are less of an issue as the impact of levodopa is to increase dopamine release. In addition, the binding of haloperidol to both presynaptic and postsynaptic receptors is something that also occurs with dopamine itself. Therefore, the intended effect of blocking D2 activation is achieved, whether this is presynaptically/postsynaptically or both.
A final limitation concerns the number of included participants in this study. As data from only 12 participants were analysed, any strong conclusions cannot be drawn from these data. For example, post hoc calculations to determine achieved power showed that the main drug effect on reaction time could only be determined with power of 0.40. Nonetheless, we observed significant drug effects on brain activation that are in accordance with previous studies using dopamine manipulations confirming effective manipulations.
| CONCLUSION
The precise implications for disorders with working memory impairment such as schizophrenia are complicated by the fact that
[18F]-DOPA imaging studies have consistently demonstrated increased dopamine synthesis capacity (e.g., Howes et al., 2007) . This would argue against the use of L-dopa, which would further elevate presynaptic dopamine function in the striatum. Studies in experimental animals combined with our findings of increased functional connectivity within an N-back related network point towards extrastriatal action of L-dopa combined with haloperidol as an important mechanism to improve cognitive performance, thus predicting utility for drugs that favour modulation of cortical dopamine projections.
Therefore, in conclusion, the present study provides initial support for the combination of an indirect dopamine agonist with a dopamine antagonist having the required effects that resemble those of increased frontal catecholamine activity, but any strong conclusion should await replication in a larger study, including a full factorial design and higher doses of L-dopa.
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FIGURE 4
An increase in functional connectivity between the right dorsolateral prefrontal cortex and frontal/sensorimotor areas was observed after haloperidol/L-dopa treatment during N-back task performance (1-, 2-, and 3-back vs. 0-back; n = 12). HAL/DOP: haloperidol/L-dopa treatment; PLC: placebo 
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